[
  {
    "trial_id": "NCT06650748",
    "mcode_mappings": [
      {
        "resourceType": "CancerCondition",
        "clinicalStatus": "active",
        "verificationStatus": "confirmed",
        "code": {
          "coding": [
            {"system": "http://snomed.info/sct", "code": "254837009", "display": "Breast Cancer"}
          ]
        },
        "subject": {"reference": "Patient/1"},
        "onsetDateTime": "2024-11-15"
      },
      {
        "resourceType": "TumorMarkerTest",
        "marker": "HR+/HER2-",
        "method": "IHC, FISH",
        "result": "HR+ (ER > 50%), HER2-",
        "date": "2024-11-15"
      },
      {
        "resourceType": "Treatment",
        "treatmentType": "Endocrine Therapy, Targeted Therapy",
        "agents": ["Dalpiciclib", "Letrozole", "CDK4/6 inhibitors"],
        "arms": ["Arm 1", "Arm 2", "Arm 3", "Arm 4"],
        "startDate": "2024-11-15",
        "endDate": "2028-04-01"
      },
      {
        "resourceType": "Outcome",
        "primaryOutcome": "PEPI score 0 + pCR proportion",
        "secondaryOutcomes": ["Ki-67 change", "pCR rate", "ORR", "CCCA rate", "Breast conservation rate", "EFS", "Adverse events"],
        "resultSummary": "Efficacy of neoadjuvant CDK4/6 inhibitors and endocrine therapy in HR+/HER2- breast cancer, stratified by multigene risk and Ki-67 response."
      }
    ],
    "source_text_fragment": "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer. The study evaluates efficacy of neoadjuvant CDK4/6 inhibitors and explores predictive biomarkers for sensitivity in HR+/HER2- breast cancer."
  }
]
